Table 1.
Characteristics and principal results of the included studies.
| Author | Year | Type of Study (Retrosp./Prosp.) | Type of Study (Comp./Non Comp.) | Pat. N | Conversion Rate | Mortality | Leaks | OS | DFS |
|---|---|---|---|---|---|---|---|---|---|
| Trastulli [22] | 2013 | retrospective | non comparative | 20 | 0 | 0 | 0 | nd | nd |
| Petz [23] | 2017 | retrospective | non comparative | 20 | 0 | 0 | 0 | nd | nd |
| Spinoglio [24] | 2018 | retrospective | comparative | 202 | 0 | 1% | 1% | 77% (5 years) | 85% (5 years) |
| Ngu [25] | 2018 | retrospective | comparative | 23 | 0 | nd | nd | nd | nd |
| Yozgatli [26] | 2019 | prospective | comparative | 96 | 0 | nd | 0 | nd | nd |
| Yang [27] | 2019 | retrospective | non comparative | 66 | 1.5% | 0 | 0 | nd | nd |
| Shulte am Esch [28] | 2019 | retrospective | non comparative | 31 | 0 | 0 | 0 | nd | nd |
| Bae [29] | 2019 | retrospective | non comparative | 43 | 0 | 0 | 2.3% | 93.6% (55 months) | 81.1% (55 months) |
| Ramachandra [30] | 2020 | retrospective | non comparative | 52 | 3.84% | 0 | 1.92% | nd | nd |
| Petz [31] | 2020 | retrospective | non comparative | 50 | 0 | 0 | 2% | nd | nd |
| Ceccarelli [32] | 2020 | retrospective | comparative | 55 | 0 | 0 | 0 | nd | nd |
| Larach [33] | 2021 | retrospective | non comparative | 20 | 0 | 0 | 0 | nd | nd |
| Siddiqui [34] | 2021 | retrospective | non comparative | 77 | 0 | 0 | 0 | 94% (3 years) | 94% (3 years) |
| Bianchi [35] | 2021 | retrospective | non comparative | 161 | 3.7% | 0 | 0.6% | nd | nd |
Pat. n: patients number; retrosp.: retrospective; prosp.: prospective; comp.: comprative; non comp.: non comparativend: not defined; OS: overall survival; DFS: disease-free survival.